Cash pulled forward: buyers are funding the company's next stage in advance, and the money keeps arriving
The model's full reasoning — Q3 2023 call → NOThe question asks whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for — that is, customers paying in advance, and whether this advance funding is growing and finances the company's next stage. Looking at the transcript, I need to find any mention of deposits, prepayments, subscriptions, memberships, or other advance payments. The company is DoorDash, a delivery platform. The business model is that customers pay for deliveries when they order, and Dashers are paid for deliveries. There's no mention of customers paying in advance for future deliveries. The only thing that could be relevant is DashPass, which is a subscription/membership program. Let me search for mentions of DashPass. In the transcript, Tony Xu mentions "improved the affordability of the programs, both for our non-DashPass members as well as for our DashPass cohorts." This is a passing mention of DashPass as a program, but there's no discussion of DashPass revenue being collected in advance, growing, or financing the company's next stage. The transcript focuses on growth in orders, GOV, new verticals, international expansion, and unit economics. There's no discussion of advance payments, deposits, prepayments, or binding commitments from customers that would finance the company's next stage. The answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
SYM · Q3 2022 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes a "very significant cost float" from "strong deferred revenue on the balance sheet" that helps fund the company's growth strategy, along with improved payable terms. This ties directly to the $11.3 billion backlog and the ability to invest aggressively in scaling deployments, inventory, and operations ahead of full revenue recognition.
IONS · Q1 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes exactly this pattern: Novartis delivered $175 million (including $75 million upfront plus $100 million equity at a premium) before the Phase IIb studies are conducted, and Bayer paid $75 million to advance IONIS-FXIRx and IONIS-FXI-LRx before full development work is complete 65-plus percent of which was already recognized in Q1.
LIND · Q2 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and if they treat this as growing and financ...YES The transcript shows management describing a clear pattern of advance bookings and forward reservations that are growing (nearly 40% year-to-date, up nearly 50% in July, highest booking day ever) and that directly de-risk and finance the next stage of growth.